Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
Z. Molvi, M. G. Klatt, T. Dao…·R. J. O'Reilly
This study identifies tumor-specific phosphopeptides presented by multiple HLA alleles, showing allele-specific immunogenicity differences for cancer immunotherapy.
S. Mecklenbräuker, P. Skoczylas, P. Biernat…·M. G. Klatt
This paper improves the isolation of tumor-specific MHC ligands through hydrophobicity and post-translational modification considerations and introduces a machine learning model for predicting MHC ligand presentation.
C. M. Bourne, S. S. Mun, T. Dao…·D. A. Scheinberg
The paper identifies tumor-specific MHC ligands in EZH2-mutated DLBCLs by combining epigenetic drugs and interferon gamma, expanding the immunopeptidome for immunotherapy targets.
S. S. Chandran, J. Ma, M. G. Klatt…·C. A. Klebanoff
The paper investigates the immunogenicity of a public neoantigen derived from mutated PIK3CA, showing it is recognized by T cells and presents a framework for immunotherapy.
R. S. Gejman, H. F. Jones, M. G. Klatt…·D. A. Scheinberg
This study introduces a high-throughput genetic platform to identify on- and off-targets of T cell receptor therapeutic agents using MHC-I ligands.